Published in Front Oncol on January 09, 2015
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst (2008) 6.00
Bile salt biotransformations by human intestinal bacteria. J Lipid Res (2005) 6.00
Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology (2003) 4.52
Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther (2014) 3.37
An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res (1998) 3.22
Clinical practice. Barrett's Esophagus. N Engl J Med (2002) 2.99
Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut (1999) 2.77
Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol (2005) 2.60
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol (2009) 2.40
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther (2011) 1.77
Short segment Barrett's esophagus--the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol (1998) 1.77
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol (2002) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res (1992) 1.62
Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer (2003) 1.55
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol (2001) 1.49
Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery (1997) 1.37
Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol (2011) 1.30
The rising incidence of gastric cardia cancer. J Natl Cancer Inst (1999) 1.29
The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc (2005) 1.28
Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology (2011) 1.25
Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.17
Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol (2008) 1.17
Barrett's esophagus: a review of the literature. J Gastrointest Surg (2011) 1.10
Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol (2012) 1.09
Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol (2006) 1.09
Gastroesophageal reflux disease in Asia: A historical perspective and present challenges. J Gastroenterol Hepatol (2011) 1.07
Proton pump inhibitor therapy and potential long-term harm. Curr Opin Endocrinol Diabetes Obes (2014) 1.06
Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther (2004) 1.05
Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol (1998) 1.02
Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol (2014) 0.96
Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. Am J Physiol Gastrointest Liver Physiol (2011) 0.94
Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev (2012) 0.89
Roles of caudal-related homeobox gene Cdx1 in oesophageal epithelial cells in Barrett's epithelium development. Gut (2009) 0.87
Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach. Am J Physiol Gastrointest Liver Physiol (2000) 0.87
Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux. Surgery (2011) 0.84
Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol (2014) 0.81
Relationships of CDXs and apical sodium-dependent bile acid transporter in Barrett's esophagus. World J Gastroenterol (2013) 0.80
Does Barrett's esophagus regress after surgery (or proton pump inhibitors)? Dig Dis (2014) 0.80
Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus. World J Gastrointest Pharmacol Ther (2014) 0.80
History of acid suppression: focus on the hospital setting. Pharmacotherapy (2003) 0.79
Risk factors associated with Barrett's epithelial dysplasia. World J Gastroenterol (2014) 0.77
Bile acid at low pH reduces squamous differentiation and activates EGFR signaling in esophageal squamous cells in 3-D culture. J Gastrointest Surg (2013) 0.76